Skip to content
Screener

Alkermes ALKS Pre-Tax Income

Pre-Tax Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$299.2M+372%
AbbVie logo
AbbVieABBV
$4.28B+175%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$64.54M-8.6%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$115M+94.9%
LBR
LB Pharmaceuticals IncLBRX
-$19.05M-259%

Segments

By geography

See full
IE-$32.2M
US$1.07M

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest expense(25,925)(46,817)
Other (expense) income, net352771(941)2,327
Total other (expense) income, net(20,229)11,861(33,875)23,558
(LOSS) INCOME BEFORE INCOME TAXES(1,876)104,839(63,802)130,328
INCOME TAX PROVISION (BENEFIT)(2,377)17,7412,17720,766
NET (LOSS) INCOME$501$87,098$(65,979)$109,562
(LOSS) EARNINGS PER ORDINARY SHARE:
(Loss) earnings per ordinary share—basic$0.00$0.53$(0.40)$0.67

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's pre-tax income?
Alkermes (ALKS) reported pre-tax income of -$1.88M in Q2 2026.
How has Alkermes's pre-tax income changed year-over-year?
Alkermes's pre-tax income decreased by 101.8% year-over-year, from $104.84M to -$1.88M.
What is the long-term trend for Alkermes's pre-tax income?
Over 4 years (2021 to 2025), Alkermes's pre-tax income has grown at a 64.8% compound annual growth rate (CAGR), from -$39.53M to $291.45M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Alkermes's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude